Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of GS-9190 with Peginterferon Alfa 2a and Ribavirin in Treatment-Naïve Genotype 1 Chronic Hepatitis C
2009-013442-86Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic hepatitis C (CHC) and hepatitis C virus infection comparing GS-9190 + Pegasys + Copegus with Placebo + Pegasys + Copegus (2 arms). Primary endpoint: Sustained virologic response (SVR). Started Sep 2009; status: completed.
02
Drugs
tegobuvir
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2009-013442-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013442-86.